

2022 Prevention of chronic non-communicable diseases  
National guidelines

Cardiovascular Therapy and Prevention (Russian Federation)  
21, 3235

DOI: [10.15829/1728-8800-2022-3235](https://doi.org/10.15829/1728-8800-2022-3235)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Thirty-year trends in the prevalence of cardiometabolic risk factors in the populations of the Russian Federation and the United States of America. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 73	0.7	10
2	Long-term survival of patients after cerebrovascular accident with prior coronary artery disease: data from the outpatient stage of REGION-M registry. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314rgBT /Overlock 10 Tf 50 73	0.784314	1
3	Assessment of the quality of mobile applications for smoking cessation and its potential for the modification of psychosocial and behavioral risk factors for cardiovascular disease. Russian Journal of Cardiology, 2022, 27, 5190.	0.4	1
4	Detection and Treatment of Hyperuricemia in Clinical Practice (According to the PROFILE Outpatient) Tj ETQq1 1 0.784314rgBT /Overlock 10 Tf 50 73	0.784314	1
5	Клинический портрет амбулаторного пациента с диабетом 2 типа. Российский журнал терапевтической практики, 2022, 3, 50-59.	0.1	0
6	The review of the bronchial asthma morbidity in the population of the Russian Federation. Pulmonologiya, 2022, 32, 651-660.	0.2	3
7	Analysis of myocardial revascularization and endpoints after a 1-year follow-up of patients with acute and chronic coronary artery disease, depending on diabetes presence. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3394.	0.4	0
8	Prospective follow-up of hypertensive patients with concomitant chronic respiratory diseases in routine practice. Part I. Characterization of adverse events. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3383.	0.4	2
9	The use of acetylsalicylic acid for prevention of cardiovascular complications in patients undergoing COVID-19. A review of current recommendations. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2022, 15, 656.	0.1	0
10	MOLECULAR MECHANISMS DEFINING APPLICATION OF GLYCINE AND ZINC COMBINATION IN CORRECTION OF STRESS AND ANXIETY MAIN MANIFESTATIONS. Farmatsiya I Farmakologiya, 2022, 10, 404-415.	0.2	5
11	Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 34	0.4	2
12	Assessment of the risks of cardiovascular system functional disorders developing in young people aged 18-25 years. Kazan Medical Journal, 2023, 104, 176-182.	0.1	1
13	Acetylsalicylic acid in the primary prevention of vascular complications in patients without clinically apparent atherosclerosis: how to balance risk and benefit?. Atherothrombosis, 2023, 12, 8-20.	0.1	0
14	Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review. Cardiosomatics, 2023, 13, 168-175.	0.2	0